← Eichor
Study identifier: NCT05800574 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Condition: Oropharynx Cancer  ·  Sponsor: Fox Chase Cancer Center

PhasePhase 2
Planned participants22
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.

This description comes directly from the study's public registry record.

Talk to the study team

Ryan Romasko  ·  2678388380  ·  ryan.romasko@fccc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Fox Chase Cancer CenterPhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05800574